Bank of Sharjah posts net profit of $73mln in H1 2025
On a quarterly basis, net profit rose to AED152 million in Q2 2025, a 31 percent increase over the AED116 million posted in Q1 2025.
The exceptional results for H1 2025 underscore the Bank's strategic focus on sustainable growth. All key performance indicators showed significant improvement, with strong contributions from both funded and non-funded income. This led to a 55 percent rise in net interest income and 51 percent increase in operating income.
At the same time, the cost-to-income ratio improved to 31 percent, supported by the Bank's continued commitment to strict cost controls. These results reflect the Bank's core strength, operational efficiency, prudent risk management, and its ongoing efforts to enhance shareholder value.
The balance sheet remains robust, with a loan-to-deposits ratio of 93 percent, and liquidity maintained at highly comfortable levels. These results also highlight the Bank's strong capital position, with capital adequacy ratio of 14 percent, and Tier1/CET1 capital ratios standing at around 13 percent.
Commenting on the Bank's results, Sheikh Mohammed bin Saud Al Qasimi, Chairman of Bank of Sharjah, said, "Bank of Sharjah has maintained strong momentum in the first half of 2025, building on the solid results achieved in the first quarter. Our record net profit reflects enhanced business performance, operational efficiency, and financial resilience. These results are driven by steady balance sheet growth, a well-diversified business mix, improved operational capabilities, and a prudent approach to risk."
Reaffirming the Board's confidence in the Bank's strategic direction, Sheikh Mohammed bin Saud Al Qasimi added, "We remain confident in our ability to deliver sustainable, long-term returns, while maintaining conservative risk management and corporate governance."
Mohamed Khadiri, CEO of Bank of Sharjah, commented, "Our strategic transformation is well underway, and our first-half performance reflects the tangible progress we are making across all business lines. We have successfully expanded and diversified our balance sheet, strengthened customer relationships, and improved cross-selling capabilities, delivering solid results."
Looking ahead, Khadiri further added, "Bank of Sharjah remains firmly focused on sustainable, profitable growth, through prudent capital deployment and sound risk governance. With a strong foundation and improving fundamentals, we are well positioned to deliver consistent returns for our shareholders while contributing to the ongoing growth and diversification of the UAE economy."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
15 minutes ago
- Zawya
Minapharm's majority shareholder Triquera raises capital through minority stake investment from Admaius Capital Partners
Cairo, Egypt - Admaius Capital Partners ('Admaius'), an Africa-focused private equity investor, and Triquera B.V. ('Triquera'), the majority shareholder in Minapharm Pharmaceuticals and Chemical Industries S.A.E. ('Minapharm'), a leading biopharmaceutical company in the Middle East and Africa and a global provider of proprietary technologies to leading biopharma players, today announced a strategic partnership following Admaius' investment in Triquera B.V. For over two decades, Minapharm has established a robust biopharmaceutical platform that combines world-class R&D with end-to-end manufacturing capabilities for complex genetically engineered therapeutic recombinant proteins and viral vectors as well as small molecules with advanced galenic formulations, operating across facilities in Cairo and Berlin. Today, Minapharm operates the largest biological drug substance and drug product facilities in the Middle East and Africa. Through its international subsidiaries, Minapharm licenses out proprietary technologies in the fields of monoclonal antibodies, vaccines, and cell and gene therapies. These technologies enable the development and production of advanced biologics that address critical unmet medical needs globally and have been incorporated into FDA-approved products, underscoring their clinical relevance and global impact. Together, Triquera and Admaius will focus on accelerating the development and production of complex genetically engineered therapies, while expanding access to high-quality, affordable recombinant proteins by investing in innovation and scaling distribution to better serve patients across underserved markets in Africa and the Middle East. In parallel, the partnership will pursue strategic acquisitions of global contract development and manufacturing organizations (CDMOs) to support Minapharm's growth in the biotech sector. This partnership reflects a shared commitment to advancing healthcare equity through innovation and aligns closely with Admaius' broader strategy of supporting mission-driven businesses and management teams in high-impact sectors across the African continent. Zilla Capital acted as the sole financial advisor to Triquera B.V. and the existing shareholders. Matouk Bassiouny served as legal counsel to Triquera B.V. and the existing shareholders. Admaius Capital Partners was advised by White and Case LLP as legal counsel and by Arthur D. Little as commercial advisor. Commenting on the investment: Dr. Wafik Bardissi, Chairman and CEO of Minapharm, said: "This partnership reflects the accelerating momentum of Minapharm's growth as we extend our leadership in biotherapeutics, cell and gene therapies, and proprietary platform technologies. With Admaius, we gain not only capital but a strategic partner whose insight, alignment, and ambition match our own. Together, we are advancing regional self-sufficiency and expanding the global reach of our innovations." Marlon Chigwende, Managing Partner of Admaius, said: 'This is a landmark transaction. The founding families have built a unique asset on the African and European continents that combines scale, growth and impact to fight cancer and other awful diseases. We are pleased to be able to partner with Triquera, Dr. Wafik and Dr. Shaheer and will help to internationalize and grow the business further.' Ahmed Rady, Managing Director of Admaius, said: 'At Admaius, we back exceptional management teams—and the team behind Minapharm is as impressive as the science, technology, and capabilities they've built across Cairo and Berlin. This partnership is about scaling a homegrown champion that combines cutting-edge global know-how with end-to-end manufacturing excellence. We're excited to support Minapharm in taking this next big step and look forward to working closely with the management team.' Dr. Shaheer Bardissi, Co-CEO of Minapharm, added: 'This strategic collaboration with Admaius will accelerate and scale Minapharm's vision of translating cutting-edge scientific innovation into affordable therapies, while advancing global scientific frontiers in immunotherapy as well as advanced therapy medicinal products, for the benefit of the broader biopharmaceutical industry.' Contacts For more information, please contact: Minapharm Christina Azmy cazmy@ (+2) (02) 24143170 Admaius Hannah Gilkes Phone number: +44 7515 958912
Zawya
15 minutes ago
- Zawya
Saudi's Canadian Medical Center seeks Tadawul transition
Saudi Arabia-based Canadian Medical Center Co. (CMC) has sought the approval from regulatory authorities to transition to the main market of Tadawul (Saudi Exchange). CMC shares debuted on the Saudi parallel market Nomu in August 2021. This past year, CMC has signed contracts with several projects backed by the $1.5 trillion Saudi sovereign investor, the Public Investment Fund, including a 93.67-riyal ($25 million) contract in May with the Saudi Arabian Mining Company (Ma'aden). (Writing by Bindu Rai, editing by Seban Scaria)
Zawya
15 minutes ago
- Zawya
Presight and Abu Dhabi Police enter strategic cooperation agreement
Abu Dhabi, UAE – Presight, a leading global AI and big data analytics company, has entered a strategic cooperation agreement with Abu Dhabi Police General Headquarters (GHQ) to develop cutting-edge artificial intelligence technologies for law enforcement. During a signing ceremony, Presight and Abu Dhabi Police jointly expressed their shared commitment to use AI to enhance law enforcement capabilities, advance public safety, and foster the development of secure, intelligent urban environments. Attending the ceremony was His Excellency Ahmed Saif bin Zaitoon AlMheiri, Commander-General of Abu Dhabi Police, His Excellency Mansoor Al Mansoori, Member of the Abu Dhabi Executive Council, Chairman of the Department of Health - Abu Dhabi, and Vice Chairman of Presight; Thomas Pramotedham, CEO of Presight; and Dr Adel Al Sharji, COO of Presight, and Mohammed AlMheiri, Chief Business Officer - Public Safety & Security. The collaboration aims to integrate the capabilities of Presight's AI-Policing Suite – a modular, future-ready solution that leverages Generative AI, AI agents, and advanced data analytics – with Abu Dhabi Police's operational excellence to address modern challenges in policing and smart city development. The partnership will accelerate the deployment of intelligent systems that enable proactive crime prevention, real-time threat detection, digital forensics, and predictive analytics. Major General/Engineer Nasir Sultan Al-Yabhouni, Director of the Leadership Affairs Sector at Abu Dhabi Police, said: 'Our partnership with Presight helps us benefit from world-leading artificial intelligence technologies that will enhance our policing capabilities and take them to new heights. This collaboration supports our efforts to maintain public safety through innovation, which means strengthening our officers' ability to respond faster, make smarter decisions, and make Abu Dhabi a safer and more secure place.' Mohammed AlMheiri, Chief Business Officer - Public Safety & Security, Presight, said: 'This strategic agreement marks a pivotal moment in the evolution of AI-driven public safety. Presight, together with Abu Dhabi Police, are enabling a new era of proactive, data-driven law enforcement, which will drive a shift towards applied intelligence-led policing defined by enhancements in decision-making and operational agility. Our platform's intelligent digital investigator, real-time threat detection, and predictive analytics capabilities empower officers to anticipate and respond to challenges with unprecedented speed and precision. Together, we are shaping a future where cities are not only smarter, but fundamentally safer.' This strategic alliance supports the transformation of public safety infrastructure, enabling enhanced decision-making and streamlined emergency response. The joint efforts will also explore innovative models to modernize law enforcement practices, emphasizing ethical AI usage and data-driven policing. The partnership is a significant step forward in realizing Abu Dhabi's vision of a future-ready, AI-enabled smart nation, reinforcing its position as a global leader in technology adoption and urban safety. About Presight Presight is an ADX-listed public company with Abu Dhabi-based G42 as its majority shareholder and is a leading global AI and big data analytics company. It combines big data, analytics, and AI expertise to serve every sector, of every scale, to create business and positive societal impact. Presight excels at all-source data interpretation to support insight-driven decision-making that shapes policy and creates safer, healthier, happier, and more sustainable societies. Today, through its range of AI-driven products and solutions, Presight is bringing Applied Intelligence to the private and public sector, enabling them to realize their AI strategy and ambitions faster. For further information, please contact media@
